|
||||||
|
 | |
| |
| |
| |
| |
|
Fusion gene ID: 7614 |
FusionGeneSummary for CMTM4_PLA2G15 |
 Fusion gene summary |
| Fusion gene information | Fusion gene name: CMTM4_PLA2G15 | Fusion gene ID: 7614 | Hgene | Tgene | Gene symbol | CMTM4 | PLA2G15 | Gene ID | 146223 | 23659 |
| Gene name | CKLF like MARVEL transmembrane domain containing 4 | phospholipase A2 group XV | |
| Synonyms | CKLFSF4 | ACS|GXVPLA2|LLPL|LPLA2|LYPLA3 | |
| Cytomap | 16q21-q22.1 | 16q22.1 | |
| Type of gene | protein-coding | protein-coding | |
| Description | CKLF-like MARVEL transmembrane domain-containing protein 4chemokine-like factor super family 4chemokine-like factor superfamily member 4 | group XV phospholipase A21-O-acylceramide synthaseLCAT-like lysophospholipaselysophospholipase 3 (lysosomal phospholipase A2)lysosomal phospholipase A2 | |
| Modification date | 20180523 | 20180524 | |
| UniProtAcc | Q8IZR5 | Q8NCC3 | |
| Ensembl transtripts involved in fusion gene | ENST00000330687, ENST00000394106, ENST00000563952, | ENST00000413021, ENST00000219345, ENST00000566188, ENST00000444212, ENST00000568599, | |
| Fusion gene scores | * DoF score | 7 X 4 X 5=140 | 3 X 3 X 3=27 |
| # samples | 7 | 3 | |
| ** MAII score | log2(7/140*10)=-1 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | log2(3/27*10)=0.15200309344505 effective Gene in Pan-Cancer Fusion Genes (eGinPCFGs). DoF>8 and MAII>0 | |
| Context | PubMed: CMTM4 [Title/Abstract] AND PLA2G15 [Title/Abstract] AND fusion [Title/Abstract] | ||
| Functional or gene categories assigned by FusionGDB annotation | |||
| * DoF score (Degree of Frequency) = # partners X # break points X # cancer types ** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10) |
| Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez |
| Partner | Gene | GO ID | GO term | PubMed ID |
| Tgene | PLA2G15 | GO:0006650 | glycerophospholipid metabolic process | 20410020 |
| Tgene | PLA2G15 | GO:0006672 | ceramide metabolic process | 20410020 |
| Fusion gene information from three resources (ChiTars (NAR, 2018), tumorfusions (NAR, 2018), Gao et al. (Cell, 2018)) * All genome coordinats were lifted-over on hg19. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
| Data type | Source | Cancer type | Sample | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
| TCGA | LD | PRAD | TCGA-EJ-5542-01A | CMTM4 | chr16 | 66655965 | - | PLA2G15 | chr16 | 68293049 | + |
| * LD: Li Ding group's fusion gene list RV: Roel Verhaak group's fusion gene list ChiTaRs fusion database |
| Open reading frame (ORF) analsis of fusion genes based on Ensembl gene isoform structure. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
| ORF | Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
| Frame-shift | ENST00000330687 | ENST00000413021 | CMTM4 | chr16 | 66655965 | - | PLA2G15 | chr16 | 68293049 | + |
| Frame-shift | ENST00000330687 | ENST00000219345 | CMTM4 | chr16 | 66655965 | - | PLA2G15 | chr16 | 68293049 | + |
| Frame-shift | ENST00000330687 | ENST00000566188 | CMTM4 | chr16 | 66655965 | - | PLA2G15 | chr16 | 68293049 | + |
| In-frame | ENST00000330687 | ENST00000444212 | CMTM4 | chr16 | 66655965 | - | PLA2G15 | chr16 | 68293049 | + |
| 5CDS-intron | ENST00000330687 | ENST00000568599 | CMTM4 | chr16 | 66655965 | - | PLA2G15 | chr16 | 68293049 | + |
| intron-3CDS | ENST00000394106 | ENST00000413021 | CMTM4 | chr16 | 66655965 | - | PLA2G15 | chr16 | 68293049 | + |
| intron-3CDS | ENST00000394106 | ENST00000219345 | CMTM4 | chr16 | 66655965 | - | PLA2G15 | chr16 | 68293049 | + |
| intron-3CDS | ENST00000394106 | ENST00000566188 | CMTM4 | chr16 | 66655965 | - | PLA2G15 | chr16 | 68293049 | + |
| intron-3CDS | ENST00000394106 | ENST00000444212 | CMTM4 | chr16 | 66655965 | - | PLA2G15 | chr16 | 68293049 | + |
| intron-intron | ENST00000394106 | ENST00000568599 | CMTM4 | chr16 | 66655965 | - | PLA2G15 | chr16 | 68293049 | + |
| intron-3CDS | ENST00000563952 | ENST00000413021 | CMTM4 | chr16 | 66655965 | - | PLA2G15 | chr16 | 68293049 | + |
| intron-3CDS | ENST00000563952 | ENST00000219345 | CMTM4 | chr16 | 66655965 | - | PLA2G15 | chr16 | 68293049 | + |
| intron-3CDS | ENST00000563952 | ENST00000566188 | CMTM4 | chr16 | 66655965 | - | PLA2G15 | chr16 | 68293049 | + |
| intron-3CDS | ENST00000563952 | ENST00000444212 | CMTM4 | chr16 | 66655965 | - | PLA2G15 | chr16 | 68293049 | + |
| intron-intron | ENST00000563952 | ENST00000568599 | CMTM4 | chr16 | 66655965 | - | PLA2G15 | chr16 | 68293049 | + |
Top |
FusionProtFeatures for CMTM4_PLA2G15 |
| Main function of each fusion partner protein. (from UniProt) |
| Hgene | Tgene |
| CMTM4 | PLA2G15 |
| Acts as a backup for CMTM6 to regulate plasma membraneexpression of PD-L1/CD274, an immune inhibitory ligand criticalfor immune tolerance to self and antitumor immunity. May protectPD-L1/CD274 from being polyubiquitinated and targeted fordegradation. {ECO:0000269|PubMed:28813410}. | Has transacylase and calcium-independent phospholipaseA2 activity (PubMed:20410020, PubMed:23958596). Catalyzes theformation of 1-O-acyl-N-acetylsphingosine and the concomitantrelease of a lyso-phospholipid (PubMed:11790796, PubMed:25727495).Has high activity with 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC) and 1,2-dioleoyl-sn-glycero-3-phosphocholine(DOPC), catalyzing the transfer of oleic acid to N-acetyl-sphingosine. Required for normal phospholipid degradation inalveolar and peritoneal macrophages and in spleen (By similarity).May have weak lysophospholipase activity (PubMed:10092508).{ECO:0000250|UniProtKB:Q8VEB4, ECO:0000269|PubMed:10092508,ECO:0000269|PubMed:11790796, ECO:0000269|PubMed:20410020,ECO:0000269|PubMed:23958596, ECO:0000269|PubMed:25727495}. |
| Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, because of limited space for viewing, we only show the protein feature retention information belong to the 13 regional features. All retention annotation result can be downloaded at . * Minus value of BPloci means that the break pointn is located before the CDS. |
| - In-frame and retained protein feature among the 13 regional features. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
| - In-frame and not-retained protein feature among the 13 regional features. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
Top |
FusionGeneSequence for CMTM4_PLA2G15 |
| For in-frame fusion transcripts, we provide the fusion transcript sequences and fusion amino acid sequences. (nt: nucleotides, aa: amino acids) |
| * Fusion amino acid sequences. |
| >In-frame_CMTM4_ENST00000330687_chr16_66655965_-_PLA2G15_ENST00000444212_chr16_68293049_+_378aa MRSGEELDGFEGEASSTSMISGASSPYQPTTEPVSQRRGLAGLRCDPDYLRGALGRLKVAQVILALIAFICIETIMACSPCEGLYFFEFV SCSAFVVTGVLLIMFSLNLHMRIPQINWNLTDLVNTGLSAFLFFIASIVLAALNHRAGAEIAAVIFGFLATAAYAVNTFLAVQKWRVSVR QQSTNDYIRARTESRDVDSRPEIQRLDTRQQPDPSHRAPEDPGAAAVSCLHQLAAALQLHMVTXEGVRADTHNQLHTAGLPQVLPGHRLX RWLAHAAGHRRAGGSHDATWRAAALPLWYWRPHTRLLLLXELPXPXPXNLLWXRRWYCELEECPAVPGLAEPPGAPSVAAGAARQRAHRD |
| * Fusion transcript sequences (only coding sequence (CDS) region). |
| >In-frame_CMTM4_ENST00000330687_chr16_66655965_-_PLA2G15_ENST00000444212_chr16_68293049_+_1135nt ATGCGGAGCGGCGAGGAGCTGGACGGCTTCGAGGGCGAGGCCTCGAGCACCTCCATGATCTCGGGCGCCAGCAGCCCGTACCAGCCCACC ACCGAGCCGGTGAGCCAGCGCCGCGGGCTGGCCGGCCTGCGCTGCGACCCCGACTACCTGCGCGGCGCGCTCGGCCGCCTCAAGGTCGCC CAAGTGATCTTGGCCCTGATTGCATTCATCTGCATAGAGACCATCATGGCATGCTCCCCGTGTGAAGGCCTCTACTTTTTTGAGTTTGTG AGCTGCAGTGCGTTTGTGGTGACTGGCGTCTTGCTGATTATGTTCAGTCTCAACCTGCACATGAGGATCCCCCAGATCAACTGGAATCTG ACAGATTTGGTCAACACTGGACTCAGCGCTTTCCTTTTCTTTATTGCTTCAATCGTACTGGCTGCTTTAAACCATAGAGCCGGAGCAGAA ATTGCTGCCGTGATATTTGGCTTCTTGGCGACTGCGGCATATGCAGTGAACACATTCCTGGCAGTGCAGAAATGGAGAGTCAGCGTCCGC CAGCAGAGCACCAATGACTACATCCGAGCCCGCACGGAGTCCAGGGATGTGGACAGTCGCCCTGAGATCCAGCGCCTGGACACGAGACAA CAACCGGATCCCAGTCATCGGGCCCCTGAAGATCCGGGAGCAGCAGCGGTCAGCTGTCTCCACCAGCTGGCTGCTGCCCTACAACTACAC ATGGTCACCTGAGAAGGTGTTCGTGCAGACACCCACAATCAACTACACACTGCGGGACTACCGCAAGTTCTTCCAGGACATCGGCTTTGA AGATGGCTGGCTCATGCGGCAGGACACAGAAGGGCTGGTGGAAGCCACGATGCCACCTGGCGTGCAGCTGCACTGCCTCTATGGTACTGG CGTCCCCACACCAGACTCCTTCTACTATGAGAGCTTCCCTGACCGTGACCCTAAAATCTGCTTTGGTGACGGCGATGGTACTGTGAACTT GAAGAGTGCCCTGCAGTGCCAGGCCTGGCAGAGCCGCCAGGAGCACCAAGTGTTGCTGCAGGAGCTGCCAGGCAGCGAGCACATCGAGAT |
| * Fusion transcript sequences (Full-length transcript). |
| >In-frame_CMTM4_ENST00000330687_chr16_66655965_-_PLA2G15_ENST00000444212_chr16_68293049_+_1567nt AGCGGACCGAGCCGCAGCCGCAGCCGGGCGGCGGGCGAGAGGCGGCGGCGGCGGGCGGGCCGCGGGCAGTCAGTCGGGCGGCGGCGGCGG CGGCGGCGGCGGCGATGCGGCGGCCCCGCTGAGTCCGCCCGCTCCTGGCGCCGGGAGCCAGCCGCGCGAGGCGGCCCGGGCCGGGCGGCA GCATGCGGAGCGGCGAGGAGCTGGACGGCTTCGAGGGCGAGGCCTCGAGCACCTCCATGATCTCGGGCGCCAGCAGCCCGTACCAGCCCA CCACCGAGCCGGTGAGCCAGCGCCGCGGGCTGGCCGGCCTGCGCTGCGACCCCGACTACCTGCGCGGCGCGCTCGGCCGCCTCAAGGTCG CCCAAGTGATCTTGGCCCTGATTGCATTCATCTGCATAGAGACCATCATGGCATGCTCCCCGTGTGAAGGCCTCTACTTTTTTGAGTTTG TGAGCTGCAGTGCGTTTGTGGTGACTGGCGTCTTGCTGATTATGTTCAGTCTCAACCTGCACATGAGGATCCCCCAGATCAACTGGAATC TGACAGATTTGGTCAACACTGGACTCAGCGCTTTCCTTTTCTTTATTGCTTCAATCGTACTGGCTGCTTTAAACCATAGAGCCGGAGCAG AAATTGCTGCCGTGATATTTGGCTTCTTGGCGACTGCGGCATATGCAGTGAACACATTCCTGGCAGTGCAGAAATGGAGAGTCAGCGTCC GCCAGCAGAGCACCAATGACTACATCCGAGCCCGCACGGAGTCCAGGGATGTGGACAGTCGCCCTGAGATCCAGCGCCTGGACACGAGAC AACAACCGGATCCCAGTCATCGGGCCCCTGAAGATCCGGGAGCAGCAGCGGTCAGCTGTCTCCACCAGCTGGCTGCTGCCCTACAACTAC ACATGGTCACCTGAGAAGGTGTTCGTGCAGACACCCACAATCAACTACACACTGCGGGACTACCGCAAGTTCTTCCAGGACATCGGCTTT GAAGATGGCTGGCTCATGCGGCAGGACACAGAAGGGCTGGTGGAAGCCACGATGCCACCTGGCGTGCAGCTGCACTGCCTCTATGGTACT GGCGTCCCCACACCAGACTCCTTCTACTATGAGAGCTTCCCTGACCGTGACCCTAAAATCTGCTTTGGTGACGGCGATGGTACTGTGAAC TTGAAGAGTGCCCTGCAGTGCCAGGCCTGGCAGAGCCGCCAGGAGCACCAAGTGTTGCTGCAGGAGCTGCCAGGCAGCGAGCACATCGAG ATGCTGGCCAACGCCACCACCCTGGCCTATCTGAAACGTGTGCTCCTTGGGCCCTGACTCCTGTGCCACAGGACTCCTGTGGCTCGGCCG TGGACCTGCTGTTGGCCTCTGGGGCTGTCATGGCCCACGCGTTTTGCAAAGTTTGTGACTCACCATTCAAGGCCCCGAGTCTTGGACTGT GAAGCATCTGCCATGGGGAAGTGCTGTTTGTTATCCTTTCTCTGTGGCAGTGAAGAAGGAAGAAATGAGAGTCTAGACTCAAGGGACACT |
Top |
FusionGenePPI for CMTM4_PLA2G15 |
| Go to ChiPPI (Chimeric Protein-Protein interactions) to see the chimeric PPI interaction in . |
| Protein-protein interactors with each fusion partner protein in wild-type (BIOGRID-3.4.160) |
| Hgene | Hgene's interactors | Tgene | Tgene's interactors |
| CMTM4 | MRPL2, APPL1, TMEM171, PTGER3, MANSC1, LPAR1, VIPR2, SLC7A1, SPPL2B, MPPE1, TRIM25 | PLA2G15 | IMMT, FBXO6, TRIM25 |
| - Retained PPIs in in-frame fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Still interaction with |
| - Lost PPIs in in-frame fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
| - Retained PPIs, but lost function due to frame-shift fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
Top |
RelatedDrugs for CMTM4_PLA2G15 |
| Drugs targeting genes involved in this fusion gene. (DrugBank Version 5.1.0 2018-04-02) |
| Partner | Gene | UniProtAcc | DrugBank ID | Drug name | Drug activity | Drug type | Drug status |
Top |
RelatedDiseases for CMTM4_PLA2G15 |
| Diseases associated with fusion partners. (DisGeNet 4.0) |
| Partner | Gene | Disease ID | Disease name | # pubmeds | Source |
Copyright 2018-Present -The University of Texas Health Science Center at Houston (UTHealth)
|